[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100588797":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":24,"centralContacts":24,"locations":24,"responsibleParty":29,"collaborators":24,"id":33,"slug":34,"hasResults":35,"nctId":36,"briefTitle":37,"officialTitle":38,"acronym":24,"eligibilityCriteria":39,"healthyVolunteers":35,"sex":40,"minAge":24,"maxAge":24,"enrollmentInfo":41,"targetDuration":24,"studyType":44,"phases":45,"briefSummary":47,"conditions":48,"keywords":51,"overallStatus":55,"whyStopped":24,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":24},{"fullName":5,"class":6},"Assiut University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Group 1 (NB-UVB Monotherapy)","EXPERIMENTAL","Standard phototherapy without additional systemic treatment.",[13],"Radiation: NB-UVB twice weekly",{"label":15,"type":10,"description":16,"interventionNames":17},"Group 2 (NB-UVB + OMP Steroids)","Combination therapy of NB-UVB + OMP Steroids to enhance immunosuppression and repigmentation.",[18],"Other: NB-UVB + dexamethasone (2.5-3 mg\u002Fweek)",[20,25],{"type":21,"name":22,"description":11,"armGroupLabels":23,"otherNames":24},"RADIATION","NB-UVB twice weekly",[9],null,{"type":6,"name":26,"description":27,"armGroupLabels":28,"otherNames":24},"NB-UVB + dexamethasone (2.5-3 mg\u002Fweek)","Combination therapy to enhance immunosuppression and repigmentation.",[15],{"type":30,"investigatorFullName":31,"investigatorTitle":32,"investigatorAffiliation":5,"oldNameTitle":24,"oldOrganization":24},"PRINCIPAL_INVESTIGATOR","ALZAHRA MOAHMED MOHAMED ABDELHAFEZ","resident at the dermatology Surgery department","100588797","immunomodulatory-effects-of-nb-uvb-and-steroids-in-vitiligo-a-study-on-cxcl11-and-temra-biomarkers-100588797",false,"NCT06946069","Immunomodulatory Effects of NB-UVB and Steroids in Vitiligo: A Study on CXCL11 and TEMRA Biomarkers","Expression of CXCL11 & TEMRA in Serum of Vitiligo Patients Treated With Narrow-band UVB","Inclusion Criteria:\n\nClinically diagnosed non-segmental vitiligo (stable for ≥3 months).\n\nFitzpatrick skin types III-V (common in the Egyptian population).\n\nNo recent systemic therapy for vitiligo (within the last 3 months).\n\nExclusion Criteria:\n\nPhotosensitivity disorders (e.g., lupus, porphyria).\n\nPregnancy or breastfeeding.\n\nActive infections, malignancies, or immunosuppressive conditions.\n\nHistory of hypertrophic scarring or melanoma.","ALL",{"count":42,"type":43},40,"ESTIMATED","INTERVENTIONAL",[46],"NA","this is a prospective, randomized controlled trial (RCT) investigating the immunological effects of narrowband UVB (NB-UVB) phototherapy-both as monotherapy and in combination with oral mini-pulse (OMP) steroids-in non-segmental vitiligo patients. The study evaluates changes in CXCL11 (a chemokine involved in T-cell recruitment) and TEMRA (terminally differentiated effector memory T cells re-expressing CD45RA) levels in serum before and after treatment.",[49,50],"Vitiligo","NB-UVB",[52,50,53,54],"vitiligo","CXCL11","TEMRA","NOT_YET_RECRUITING","2025-04-19",{"date":58,"type":59},"2025-04-27","ACTUAL",{"date":61,"type":43},"2025-09-01",{"date":63,"type":43},"2026-09-30",{"name":5,"class":6}]